Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1651 1655 1656
This examiner grants 78% of resolved cases
Anand U. Desai has managed 915 resolved cases within Tech Center 1600 and Art Unit 1651. The examiner has an allowance rate of 78.5 percent, providing a reliable baseline for applicants. The median days to allowance is 1130, which is the typical time required to reach a grant for the 915 cases processed.
An interview lift of 12.7 percent indicates that direct discussion with the examiner improves the chances of allowance beyond the 78.5 percent base rate. This 12.7 percent lift is a strategic consideration for practitioners looking to resolve issues more efficiently. The 1130-day median pendency suggests a moderate timeline for prosecution that applicants should prepare for at the outset.
With 915 resolved cases, the data for Desai is robust and reflects a stable prosecution environment. The 78.5 percent allowance rate and 12.7 percent interview lift are the primary metrics for evaluating success in Art Unit 1651. Understanding the 1130-day median to allowance helps in planning the necessary resources for a successful patent application.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18018981 | METHODS TO CONTROL LIPOKINE CONCENTRATIONS AND USES THEREOF | Final Rejection | Ohio State Innovation Foundation |
| 18693797 | COMPOSITIONS AND METHODS LOWERING GLYCEMIC RESPONSE TO IMPROVE SLEEP QUALITY AND/OR SUBSEQUENT BEHAVIOURAL OUTCOMES | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 19196457 | IgE PROTEASES AND USES THEREOF | Non-Final OA | Seismic Therapeutic, Inc. |
| 18261203 | METHODS AND PLATFORMS FOR PROMOTING ANTIGEN-SPECIFIC TOLERANCE IN THE TREATMENT OF TYPE 1 DIABETES AND GRAFT REJECTION AND COMPOSITIONS RELATING THERETO | Non-Final OA | University of Maryland, Baltimore |
| 18533639 | ELASTOMERIC PROTEINS | Non-Final OA | BOLT THREADS, INC. |
| 17632222 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE | Final Rejection | Expression Therapeutics, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy